Saccharomyces cerevisiae for autism spectrum disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jan 2024: Trial started, NCT06568588
  2. 23 Aug 2024: Trial registered, NCT06568588

The trials

NCT06568588: Effects of Probiotic Consumption in Children With Autism Spectrum Disorder (ASD)

State
Under way
Phase
Phase 2
People
66 planned
Started
6 Jan 2024
Primary completion
Aug 2026
Arms
First four months with Sb (Group A), Last four months with Sb (Group B)
Results
None posted
  1. 6 Jan 2024: Trial started
  2. 23 Aug 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745, Saccharomyces Boulardii 250 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.